Tumour-Penetrating Lipid Nanodiscs for Immunity

The field of oncology is undergoing a transformative shift, moving beyond traditional treatments toward innovative immunotherapies that harness the body's own defence mechanisms. While these approaches show immense promise, a significant challenge remains: delivering therapeutic agents directly and effectively to the tumour site. At Creative Biolabs, we're dedicated to helping our partners overcome these hurdles by leveraging cutting-edge science. A recent and highly promising development in this area is the use of tumour-penetrating lipid nanodiscs, a technology supported by robust scientific literature.

Activating the Immune System: The STING Pathway

Targeting the Stimulator of Interferon Genes (STING) pathway represents a promising strategy in immuno-oncology. STING, a key innate immune sensor, detects danger-associated molecular patterns from tumors. Its activation by agonists initiates a robust inflammatory response, recruiting cytotoxic T-cells to eliminate cancer cells.

A major translational challenge is the targeted delivery of these STING agonists. As small molecules, they suffer from rapid systemic clearance and dose-limiting toxicities due to non-specific inflammation. Therefore, developing an advanced delivery system is essential to selectively localize agonists to the tumor site, thereby enhancing therapeutic efficacy and improving safety.

The Strategic Advantage of Lipid Nanodiscs (LNDs)

Unlike spherical nanoparticles, LNDs are self-assembling, discoidal (disc-shaped) nanoparticles. This distinct geometry offers a crucial advantage in navigating the intricate tumour microenvironment. Scientific studies have demonstrated that the non-spherical shape of LNDs allows them to penetrate solid tumours more efficiently than their spherical counterparts. This enhanced penetration capability means that a greater number of therapeutic molecules can reach and interact with tumour cells, leading to a more robust therapeutic effect. The structural flexibility and self-assembly properties of LNDs also make them highly adaptable for encapsulating a variety of payloads, from small molecules to complex proteins.

Experimental Insights: Tumour-Penetrating Nanodiscs for Antitumour Immunity

Drawing from a recent landmark study published in Nature Communications, we highlight the key experimental strategies that are driving innovation in DNA LNP development. The research provides a blueprint for a systematic approach to overcoming the inherent challenges of plasmid DNA delivery.

• Fabrication and Characterization of LND−CDNs

Researchers successfully synthesized LNDs loaded with CDN-PEG-lipids. The study meticulously characterized the physicochemical properties of these nanodiscs, confirming their discoidal shape and uniform size distribution. These foundational experiments established a stable and reproducible formulation, a prerequisite for all subsequent in vitro and in vivo studies.

Fig. 1 Design and characterization of nanoparticles for STING agonist delivery. ¹

• Superior Tumour Penetration of Lipid Nanodiscs

A pivotal finding demonstrated that LNDs exhibited a unique ability to penetrate solid tumours more effectively than conventional spherical liposomes. This superior penetration was visualized and quantified, showing that LNDs could reach the majority of tumour cells. This experimental insight underscores the critical role of nanoparticle shape in overcoming the physical barriers of the tumour microenvironment.

Fig. 2 LND-CDN has better passive diffusion and tumor penetration capabilities than liposome-CDN. ¹

• Robust Antitumour Efficacy and Immune Memory

Most importantly, a single dose of the LND−CDNs induced the complete rejection of established tumours in a preclinical model. This remarkable outcome was accompanied by the development of long-term immune memory, preventing the recurrence of cancer upon tumour rechallenge. These compelling in vivo results highlight the significant therapeutic potential of this approach.

Fig. 3 The anti-tumor effect of LND-CDN in multiple homologous tumor models. ¹

• Systemic Immune Response and T-cell Activation

Further mechanistic insights revealed how LND-CDN uptake by cancer cells correlated with a powerful systemic immune response. The delivery system promoted the co-localization of the STING agonist and tumour antigens in dendritic cells, which are critical for presenting antigens to and activating T-cells. This evidence provides a deeper understanding of how local tumour treatment can trigger a widespread, systemic immune reaction.

Fig. 4 The co-localization of LND-CDN and antigens in lymph node dendritic cells leads to effective anti-tumor T-cell response. ¹

The research highlighted above demonstrates a significant advancement in targeted drug delivery. By overcoming the physical barriers of the tumour microenvironment, LNDs offer a promising platform for developing effective immunotherapies. This breakthrough showcases the power of innovative lipid-based systems in clinical applications. For a deeper understanding or to explore how this research can inform your next project, please contact our team of experts.

Related Products & Services

At Creative Biolabs, we provide a comprehensive suite of products and services to help you accelerate your research and development in lipid-based drug delivery. Our offerings are designed to address the challenges and opportunities presented by advanced delivery systems like LNDs.

Resources

For Research Use Only. Not For Clinical Use